Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06274411

Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention

Led by Beijing Anzhen Hospital · Updated on 2026-05-13

176

Participants Needed

1

Research Sites

88 weeks

Total Duration

On this page

Sponsors

B

Beijing Anzhen Hospital

Lead Sponsor

W

Wuhan Asia Heart Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this multicenter, randomized trial is to compare standby cannulated ECMO versus prophylactic ECMO in patients undergoing high-risk percutaneous coronary intervention (PCI). The main question it aims to answer is : • If standby cannulated ECMO as compared with prophylactic ECMO will improve the outcomes in patients undergoing high-risk PCI

CONDITIONS

Official Title

Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Clinician decision to perform PCI with ECMO support
  • Age 18 years or older
  • Compromised heart function with ejection fraction less than 35%, or at risk of hemodynamic deterioration, or intervention on last patent coronary conduit or unprotected left main artery, or complex 3-vessel disease with SYNTAX score of 33 or higher
  • Informed consent provided
Not Eligible

You will not qualify if you...

  • Cardiogenic shock requiring inotropes, pressors, or mechanical support to maintain systolic blood pressure above 90 mmHg
  • Moderate to severe aortic insufficiency
  • Severe peripheral vascular disease
  • Creatinine level 4 mg/dL or higher
  • Liver dysfunction with liver enzymes and bilirubin levels elevated to 3 times the upper limit of normal or more
  • History of stroke or transient ischemic attack within the past month
  • Abnormal blood clotting defined as platelet count 50,000/mm3 or lower or fibrinogen 1.50 g/L or lower
  • Allergy or intolerance to heparin, aspirin, ADP receptor inhibitors, or documented heparin-induced thrombocytopenia

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Beijing Anzhen Hospital

Beijing, Beijing Municipality, China, 100029

Actively Recruiting

Loading map...

Research Team

X

Xiaotong Hou, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here